Diamyd Medical
Sweden - StockholmBiotechnology
Focus: Diamyd Medical is a Swedish public biotech focused on diabetes-targeting biologics, primarily developing immunotherapies for Type 1 Diabetes and related metabolic diseases. The company operates at mid-stage clinical development with a concentrated pipeline in GAD-based and recombinant protein therapeutics.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Diamyd Medical
AI assessmentNot HiringNo open roles listed right now. Follow Diamyd Medical to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
GAD-Alum
Diabetes Mellitus, Type 1Clinical Trials (1)
NCT02352974GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)
Phase 1Help build intelligence for Diamyd Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.